Human Health Risks of Engineered Nanomaterials

Elder, Alison; Lynch, Iseult; Grieger, Khara; Chan-Remillard, S.; Gatti, Antonietta; Gnewuch, H; Kenawy, El‐Refaie; Korenstein, Rafi; Kuhlbusch, Thomas A. J.; Linker, F; Matias, S; Monteiro‐Riviere, Nancy A.; Pinto, Vrs; Rudnitsky, Robert; Savolainen, Kai; Shvedova, Anna A.

doi:10.1007/978-1-4020-9491-0_1

Cited by 16 publications

(3 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, upon ingestion of nanomaterials by humans and animals they enter the alimentary tract, reach the circulatory system and are carried over via the liver and spleen [ 35 , 154 , 155 ], whereas, inhalation and skin exposure to nanomaterials allows for their penetration through the skin tissues and nerve cells [ 152 , 155 ]. Inhalation of TiO 2 NPs was identified to have an effect in the development of lung cancer [ 154 ].…”

Section: Nanoantifungals: Can These Be the Future Innovations In Veterinary Biomedicine?mentioning

confidence: 99%

Antifungal Nano-Therapy in Veterinary Medicine: Current Status and Future Prospects

Alghuthaymi

Hassan

Kalia

et al. 2021

JoF

View full text Add to dashboard Cite

The global recognition for the potential of nanoproducts and processes in human biomedicine has given impetus for the development of novel strategies for rapid, reliable, and proficient diagnosis, prevention, and control of animal diseases. Nanomaterials exhibit significant antifungal and antimycotoxin activities against mycosis and mycotoxicosis disorders in animals, as evidenced through reports published over the recent decade and more. These nanoantifungals can be potentially utilized for the development of a variety of products of pharmaceutical and biomedical significance including the nano-scale vaccines, adjuvants, anticancer and gene therapy systems, farm disinfectants, animal husbandry, and nutritional products. This review will provide details on the therapeutic and preventative aspects of nanoantifungals against diverse fungal and mycotoxin-related diseases in animals. The predominant mechanisms of action of these nanoantifungals and their potential as antifungal and cytotoxicity-causing agents will also be illustrated. Also, the other theragnostic applications of nanoantifungals in veterinary medicine will be identified.

show abstract

Section: Nanoantifungals: Can These Be the Future Innovations In Veterinary Biomedicine?mentioning

confidence: 99%

Antifungal Nano-Therapy in Veterinary Medicine: Current Status and Future Prospects

Alghuthaymi

Hassan

Kalia

et al. 2021

JoF

View full text Add to dashboard Cite

show abstract

“…A positive correlation between an increased atmospheric particulate concentration and short-term morbidity and mortality has been described epidemiologically [ 108 , 109 ]. Entry of airborne particles through the respiratory system permits translocation of NPs to other primary organs in small quantities [ 110 – 113 ]. Depending upon the physicochemical characteristics of the inhaled NPs, the respiratory system can be one of the primary sites of toxicity.…”

Section: Introductionmentioning

confidence: 99%

Inhaled nanomaterials and the respiratory microbiome: clinical, immunological and toxicological perspectives

et al. 2018

View full text Add to dashboard Cite

Our development and usage of engineered nanomaterials has grown exponentially despite concerns about their unfavourable cardiorespiratory consequence, one that parallels ambient ultrafine particle exposure from vehicle emissions. Most research in the field has so far focused on airway inflammation in response to nanoparticle inhalation, however, little is known about nanoparticle-microbiome interaction in the human airway and the environment. Emerging evidence illustrates that the airway, even in its healthy state, is not sterile. The resident human airway microbiome is further altered in chronic inflammatory respiratory disease however little is known about the impact of nanoparticle inhalation on this airway microbiome. The composition of the airway microbiome, which is involved in the development and progression of respiratory disease is dynamic, adding further complexity to understanding microbiota-host interaction in the lung, particularly in the context of nanoparticle exposure. This article reviews the size-dependent properties of nanomaterials, their body deposition after inhalation and factors that influence their fate. We evaluate what is currently known about nanoparticle-microbiome interactions in the human airway and summarise the known clinical, immunological and toxicological consequences of this relationship. While associations between inhaled ambient ultrafine particles and host immune-inflammatory response are known, the airway and environmental microbiomes likely act as intermediaries and facilitate individual susceptibility to inhaled nanoparticles and toxicants. Characterising the precise interaction between the environment and airway microbiomes, inhaled nanoparticles and the host immune system is therefore critical and will provide insight into mechanisms promoting nanoparticle induced airway damage.

show abstract

“…While engineered NPs have recently been widely used owing to their unique physiochemical properties, there are growing concerns about their safety and biological effects. − Therefore, cost-effective, high-throughput toxicological testing is required to keep pace with the rapid diversification of the newly developed NPs. In this context, real-time, cost-efficient NP-analysis devices are also useful in toxicological tests.…”

mentioning

confidence: 99%

Monitoring the Effective Density of Airborne Nanoparticles in Real Time Using a Microfluidic Nanoparticle Analysis Chip

et al. 2021

View full text Add to dashboard Cite

Determining the effective density of airborne nanoparticles (NPs; particles smaller than 100 nm in diameter) at a point of interest is essential for toxicology and environmental studies, but it currently requires complex analysis systems comprising several high-precision instruments as well as a specially trained operator. To address these limitations, a field-portable and cost-efficient microfluidic NP analysis device is presented, which provides quantitative information on the effective density and size distribution of NPs in real time. Unlike conventional analysis systems, the device can operate in a standalone mode because of the chip operating principle based on the electrostatic/inertial classification and electrical detection methods. Moreover, the device is both compact (16.0 × 10.9 × 8.6 cm3) and light (950 g) owing to the hardware strip down enabled by integrating the essential functions for effective density analysis on a single chip. Quantitative experiments performed to simulate real-life applications utilizing effective density (i.e., effective density-based morphology analysis on engineered NPs and multi-parametric NP monitoring in ambient air) demonstrate that the developed device can be used as an analysis tool in toxicological studies as an on-site sensor for the monitoring of individual NP exposure and environments, for quality monitoring of engineered NPs via aerosol synthesis, and other applications.

show abstract

Human Health Risks of Engineered Nanomaterials

Cited by 16 publications

References 85 publications

Antifungal Nano-Therapy in Veterinary Medicine: Current Status and Future Prospects

Antifungal Nano-Therapy in Veterinary Medicine: Current Status and Future Prospects

Inhaled nanomaterials and the respiratory microbiome: clinical, immunological and toxicological perspectives

Monitoring the Effective Density of Airborne Nanoparticles in Real Time Using a Microfluidic Nanoparticle Analysis Chip

Contact Info

Product

Resources

About